{
    "eid": "2-s2.0-85106144001",
    "title": "Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: Role of HCV core antigen monitoring and improvement of liver stiffness and steatosis",
    "cover-date": "2021-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [],
    "authors": [
        "Maneerat Chayanupatkul",
        "Salyavit Chittmittraprap",
        "Pornpitra Pratedrat",
        "Natthaya Chuaypen",
        "Anchalee Avihingsanon",
        "Pisit Tangkijvanich"
    ],
    "citedby-count": 4,
    "ref-count": 50,
    "ref-list": [
        "Global epidemiology and burden of HCV infection and HCV-related disease",
        "Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource",
        "Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand",
        "Epidemiology and natural history of HCV infection",
        "Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study",
        "Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin D levels",
        "Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis",
        "What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?",
        "Elbasvir/grazoprevir: a review in chronic HCV genotypes 1 and 4",
        "Liver biopsy",
        "Sampling variability of liver fibrosis in chronic hepatitis C",
        "Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection",
        "Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment",
        "Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis",
        "Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis",
        "HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies",
        "Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays",
        "Non invasive evaluation of portal hypertension using transient elastography",
        "American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases",
        "Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection",
        "High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotypic resistance testing among human immunodeficiency virus/hepatitis C virus-coinfected men who have sex with men",
        "Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label Phase 2 trial",
        "Efficacy and safety of elbasvir/ grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study",
        "Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis",
        "Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial",
        "Elbasvir/ grazoprevir for patients with hepatitis C virus infection and inherited blood disorders: a Phase III study",
        "Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination Phase 3 study",
        "Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection",
        "The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan",
        "Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network",
        "Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort",
        "Performance of transient elastography for the staging of liver fibrosis: a meta-analysis",
        "The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis",
        "Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression",
        "AGA Clinical Practice Update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review",
        "Liver stiffness at the time of sustained virological response predicts the clinical outcome in people living with human immunodeficiency virus and hepatitis C virus with advanced fibrosis treated with direct-acting antivirals",
        "Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals",
        "Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response",
        "Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data",
        "Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3",
        "Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b",
        "Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response",
        "Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter",
        "Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals",
        "Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort",
        "Clinical utility of HCV core antigen detection and quantification in the diagnosis and management of patients with chronic hepatitis C receiving an all-oral, interferon-free regimen",
        "Quantification of core antigen monitors efficacy of direct-acting antiviral agents in patients with chronic hepatitis C virus infection",
        "EASL recommendations on treatment of hepatitis C 2018",
        "Magnitude and kinetics of decrease in liver stiffness after antiviral therapy in patients with chronic hepatitis C: a systematic review and meta-analysis"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Hepatitis and Liver Cancer",
        "Chulalong-korn University",
        "Abbott Laboratories Ltd",
        "Merck & Co., Inc.",
        "Chulalongkorn University",
        "Thailand Research Fund"
    ]
}